229- van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal
neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235–40. - Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with
inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-
tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64. - Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive thera-
pies in patients with immune-mediated diseases: a systematic review and meta-analysis.
Gastroenterology. 2016;151(1):97–109.e4. - Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel
disease therapy. Inflamm Bowel Dis. 2010;16:2168–72.
13 Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy